Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamasurg.2025.0158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcatheter edge-to-edge repair for the management of secondary mitral regurgitation - CRT 2025 Beyond the Guidelines.
Cardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFComprehensive assessment of triclosan-induced toxicity: impacts on zebrafish development, mammalian cell viability and microbial activity.
Adv Med Sci
September 2025
Chair and Department of Medical Microbiology, Medical University of Lublin, Lublin, Poland. Electronic address:
Purpose: The aim of the study was to evaluate the toxicity of triclosan in the Danio rerio model and mammalian cells, as well as to assess its antimicrobial and antibiofilm activity against selected bacterial pathogens.
Methods: Triclosan toxicity was assessed in Danio rerio embryos in accordance with OECD Test Guideline 236: Fish Embryo Acute Toxicity (FET) Test. Cytotoxicity was evaluated in vitro using the MTT assay on human dermal fibroblasts (BJ) and rat cardiomyoblasts (H9c2).
Biomarker-based pre-heart failure screening in a middle-aged rural population.
J Cardiol
September 2025
Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Epidemiology, Disease Control, and Prevention, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. Electronic address:
Background: Guidelines recommend biomarker-based screening for pre-heart failure (pre-HF) among at-risk populations. Although the asymptomatic nature of pre-HF necessitates proactive screening, real-world implementation remains understudied. This retrospective study analyzed data from a regional pre-HF screening initiative, integrated into annual health screenings, to evaluate: (1) the prevalence of elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, (2) associated echocardiographic findings, and (3) adherence across the screening-to-consultation pathway.
View Article and Find Full Text PDFHypoalbuminemia in heart failure: pathophysiology, clinical implications, and management strategies.
Heart Fail Rev
September 2025
Department of Medicine, Division of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
Hypoalbuminemia is commonly seen in patients with heart failure and is associated with worse outcomes. Multiple pathophysiologic mechanisms can contribute to low albumin levels in heart failure patients, such as malnutrition, hepatic congestion, inflammation, and protein-losing enteropathy. Hypoalbuminemia can exacerbate heart failure symptoms and contributes to pulmonary edema by reducing plasma oncotic pressure, thereby favoring fluid movement into the interstitial and alveolar spaces.
View Article and Find Full Text PDFCancer and Post-Therapy Cardiotoxicity Risk in Adolescents, Young Adults, and Adults With Down Syndrome.
Compr Physiol
October 2025
Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
The median life expectancy of people with Down syndrome has increased substantially over the past several decades, from 4 years in 1970 to 53 years in 2010. Despite the recent improvement in survival, there is little data about the prevalence of age-related diseases, including age-related malignancies, and the impact of standard cancer treatments on cardiovascular health. We retrospectively reviewed medical records for age- and sex-matched patients ≥ 15 years old with and without Down syndrome using the TriNetX platform to identify the prevalence of malignancies and explore cardiovascular outcomes after treatment with anthracyclines.
View Article and Find Full Text PDF